Skip to Main Content

Paper Details

Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity.
Nat Genet
27
2022
D1, ICB, POLD1, POLD1 mutated, POLD1 mutations, POLE, Patients, Pold1, Pole, T cell, T cell receptor, TCR, hypermutation, mutant POLE, patients, syngeneic tumors, tumor, tumors
Author NameAffiliation
Nadeem RiazMemorial Sloan Kettering Cancer Center
Mark LeeMemorial Sloan Kettering Cancer Center
Vladimir MakarovCenter for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic Foundation
Vladimir MakarovLerner Research Institute, Cleveland Clinic
Vladimir MakarovCenter for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic Foundation
Vladimir MakarovLerner Research Institute, Cleveland Clinic
Fengshen KuoMemorial Sloan Kettering Cancer Center
Daniel W KellyMemorial Sloan Kettering Cancer Center
Xin PeiMemorial Sloan Kettering Cancer Center
Mithat GonenMemorial Sloan Kettering Cancer Center
Luc G T MorrisMemorial Sloan Kettering Cancer Center
Timothy A ChanCenter for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic Foundation
Timothy A ChanLerner Research Institute, Cleveland Clinic
Timothy A ChanMemorial Sloan Kettering Cancer Center
Timothy A ChanTaussig Cancer Institute, Cleveland Clinic Foundation
Timothy A ChanNational Center for Regenerative Medicine
Timothy A ChanCenter for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic Foundation
Timothy A ChanLerner Research Institute, Cleveland Clinic
Timothy A ChanMemorial Sloan Kettering Cancer Center
Timothy A ChanTaussig Cancer Institute, Cleveland Clinic Foundation
Timothy A ChanNational Center for Regenerative Medicine
  • 1 - 21

Datasets

Release 1.2